The clinical trial ecosystem is entering a phase of consolidation and reinvention driven by the collapse of boundaries between functions, data, and even companies themselves.

In a Q&A, an FDA spokesperson discusses efforts to reduce misinformation about biosimilars through education, the agency’s collaboration with global regulators to streamline development, and its work ...

Early-stage regulatory strategy is becoming a powerful driver of speed, risk reduction, and commercial value in drug ...

CDMOs are re-evaluating a reliance on China and increasingly turning to nearshoring and friendshoring for supply chain ...

The collaboration achieves synergy across the entire value chain from AI-driven design and antibody development to payload-linker chemical synthesis and clinical development, establishing a complete, ...

Too often, manufacturing is treated as an afterthought in drug development—a downstream function to be addressed once R&D milestones are met. But in today’s complex and competitive environment, ...

Learn how AI is transforming predictions of drug-induced liver injury and aiding drug development for safer therapeutics.

Explore how Insilico collaborates with Servier to advance AI-driven drug discovery in oncology for unmet medical needs.

SK Chemicals said Friday it has signed a memorandum of understanding with Nextgen Bioscience to strengthen cooperation on the discovery and joint development of new drug candidates, signifying its ...

Insilico Medicine (“Insilico”), a world-leading artificial intelligence (AI)-driven drug discovery company, today announced a ...

Insilico Medicine ("Insilico"), a world-leading artificial intelligence (AI)-driven drug discovery company, today announced a multi-year research and development (R&D) collaboration with Servier, an ...